| Morningstar Fund Report | 05/04/2025 |  |
Legal & General Global Health & Pharmaceuticals Index Trust C Class Accumulation |
| Performance History | 31/03/2025 |
| Growth of 1,000 (GBP) | Advanced Graph |
 | Fund | 19.6 | 5.0 | -1.9 | 3.3 | 0.3 |
| +/-Cat | 10.2 | 9.7 | 1.2 | 2.3 | 1.9 |
| +/-B’mrk | 1.4 | -0.8 | 0.6 | 0.6 | -1.6 |
| Category: Sector Equity Healthcare | ||||||
| Category Benchmark: Morningstar Gbl Health TME ... | ||||||
| Key Stats | ||
| NAV 04/04/2025 | GBX 75.71 | |
| Day Change | -1.88% | |
| Morningstar Category™ | Sector Equity Healthcare | |
| IA (formerly IMA) Sector | Healthcare | |
| ISIN | GB00BJ2JPG83 | |
| Fund Size (Mil) 31/03/2025 | GBP 950.53 | |
| Share Class Size (Mil) 03/04/2025 | GBP 368.11 | |
| Max Initial Charge | - | |
| Ongoing Charge 21/03/2025 | 0.20% | |
| Investment Objective: Legal & General Global Health & Pharmaceuticals Index Trust C Class Accumulation |
| The objective of the Fund is to track the performance of the FTSE World Index - Health Care (the “Benchmark Index”) on a net total return basis before fees and expenses are applied. Therefore, the Fund’s performance may differ from the Benchmark Index due to the deduction of fees and expenses and the impact of any tracking error factors. The Benchmark Index is comprised of shares in companies engaged in health, pharmaceuticals and biotechnology. The Fund is a Replicating Fund as it seeks to replicate as closely as possible the constituents of the Benchmark Index by holding all, or substantially all, of the assets comprising the Benchmark Index in similar proportions to their weightings in the Benchmark Index. The Fund will have at least 90% exposure to assets that are included in the Benchmark Index. |
| Returns | |||||||||||||
|
| Management | ||
Manager Name Start Date | ||
Not Disclosed 30/09/2013 | ||
Inception Date 22/02/2019 | ||
| Category Benchmark | |
| Fund Benchmark | Morningstar Benchmark |
| FTSE World Health&Pharmaceutical PR GBP | Morningstar Gbl Health TME NR USD |
| Portfolio Profile for Legal & General Global Health & Pharmaceuticals Index Trust C Class Accumulation | 28/02/2025 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| Top 5 Holdings | Sector | % |
 Eli Lilly and Co |  Healthcare | 9.46 |
| UnitedHealth Group Inc | Healthcare | 5.70 |
| Johnson & Johnson | Healthcare | 5.19 |
| AbbVie Inc | Healthcare | 4.79 |
| Novo Nordisk AS Class B | Healthcare | 3.63 |
 | ||
 Increase Decrease  New since last portfolio | ||
| Legal & General Global Health & Pharmaceuticals Index Trust C Class Accumulation | ||
| Growth Of 1000 (GBP) | 31/03/2025 |
|
| Annual Returns (GBP) | 31/03/2025 | |||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 31/03 | |||
| Price Return | 9.20 | 19.62 | 5.02 | -1.90 | 3.30 | 0.29 | ||
| +/- Category | -8.28 | 10.19 | 9.69 | 1.22 | 2.33 | 1.89 | ||
| +/- Category Index | - | 1.41 | -0.79 | 0.63 | 0.60 | -1.64 | ||
| % Rank in Category | 67 | 20 | 21 | 46 | 33 | 36 | ||
| Trailing Returns (GBP) | 04/04/2025 | ||
| Total Returns | +/- Category | +/- Category Index | |
| 1 Day | -1.88 | -0.48 | -0.19 |
| 1 Week | -4.12 | -1.00 | -1.59 |
| 1 Month | -8.89 | -1.19 | -1.76 |
| 3 Months | -4.10 | 0.76 | -1.48 |
| 6 Months | -8.73 | -0.21 | -1.90 |
| YTD | -3.25 | 0.36 | -2.17 |
| 1 Year | -5.59 | 1.28 | -1.67 |
| 3 Years Annualised | 1.18 | 3.57 | -0.34 |
| 5 Years Annualised | 7.37 | 1.71 | -0.48 |
| 10 Years Annualised | - | - | - |
| Category: Sector Equity Healthcare | |||
| Category Index: Morningstar Gbl Health TME NR USD | |||
| Quarterly Returns (GBP) | 31/03/2025 | |||
| Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 | |
| 2025 | 0.29 | - | - | - |
| 2024 | 8.29 | 0.73 | -0.23 | -5.08 |
| 2023 | -4.69 | 0.05 | 1.79 | 1.05 |
| 2022 | -0.20 | -1.74 | 3.11 | 3.87 |
| 2021 | -0.50 | 8.32 | 4.72 | 5.98 |
| 2020 | -6.13 | 14.59 | 0.86 | 0.65 |
| Morningstar Rating™(Relative to Category) | 28/02/2025 | ||||||||||||||||||||
| |||||||||||||||||||||
| Category : Sector Equity Healthcare | Click here to see our Methodology | ||||||||||||||||||||
| Volatility Measurements | 31/03/2025 | ||||||||||
| |||||||||||
| Modern Portfolio Statistics | 31/03/2025 | 31/03/2025 |
| Standard Index | Best Fit Index | |
| Morningstar Gbl Health TME NR USD | Morningstar Gbl Health TME NR USD | |
| 3-Yr Beta | 0.96 | 0.96 |
| 3-Yr Alpha | -0.67 | -0.67 |
| Investment Style Details | 28/02/2025 | ||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||
| Category: Sector Equity Healthcare | |||||||||||||||||||||||||||||||||||||||||
| Asset Allocation | 28/02/2025 |
| ||||||||||||||||||||||||||
| World Regions | 28/02/2025 | ||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||
| Category: Sector Equity Healthcare | |||||||||||||||||||||||||||||||||||||||||||
| Sector Weightings | 28/02/2025 | |||||||||||||||
| ||||||||||||||||
| Category: Sector Equity Healthcare | ||||||||||||||||
| Top 10 Holdings | 28/02/2025 |
| Portfolio NEW | |
| Total Number of Equity Holdings | 183 |
| Total Number of Bond Holdings | 0 |
| Assets in Top 10 Holdings | 43.45 |
| Name | Sector | Country | % of Assets | ||
| Eli Lilly and Co | | United States | 9.46 | ||
| UnitedHealth Group Inc | | United States | 5.70 | ||
| Johnson & Johnson | | United States | 5.19 | ||
| AbbVie Inc | | United States | 4.79 | ||
| Novo Nordisk AS Class B | | Denmark | 3.63 | ||
| Roche Holding AG | | Switzerland | 3.10 | ||
| Abbott Laboratories | | United States | 3.07 | ||
| Merck & Co Inc | | United States | 3.03 | ||
| Novartis AG Registered Shares | | Switzerland | 2.84 | ||
| AstraZeneca PLC | | United Kingdom | 2.64 | ||
| Increase Decrease New since last portfolio | |||||
| Category: Sector Equity Healthcare | |||||
| Management | ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| Fees and Expenses | ||||||||||||
| ||||||||||||
| Purchase Details | ||||||||
| ||||||||
| ||||||||